Marvel Biosciences Corp. (TSXV:MRVL)

Marvel Biosciences Balance Sheet

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2025	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Cash & Equivalents	0.63	0.13	0.35	0.56	0.59	2.39
Cash & Short-Term Investments	0.63	0.13	0.35	0.56	0.59	2.39
Cash Growth	660.66%	-62.73%	-37.88%	-6.17%	-75.21%	964.52%
Other Receivables	0.03	0.17	0.12	0.08	0.06	0.06
Receivables	0.03	0.17	0.12	0.08	0.06	0.06
Prepaid Expenses	0.02	0.03	0.03	0.03	0.01	-
Other Current Assets	-	-	-	-	0.25	0.02
Total Current Assets	0.68	0.33	0.49	0.67	0.91	2.47
Property, Plant & Equipment	-	-	-	-	-	0
Total Assets	0.68	0.33	0.49	0.67	0.91	2.47
Accounts Payable	1.61	1.5	1.35	1.21	0.26	0
Accrued Expenses	0.42	0.52	0.26	0.18	0.43	0.11
Current Portion of Long-Term Debt	2.31	2.31	1.71	-	-	-
Other Current Liabilities	-	-	-	-	0.03	-
Total Current Liabilities	4.33	4.33	3.32	1.39	0.72	0.11
Long-Term Debt	-	-	-	1	-	-
Total Liabilities	4.33	4.33	3.32	2.39	0.72	0.11
Common Stock	9.15	8.46	7.58	7.13	6.86	6.46
Additional Paid-In Capital	-	-	-	-	0.12	0.1
Retained Earnings	-13.25	-12.91	-10.7	-9.05	-6.76	-4.2
Comprehensive Income & Other	0.45	0.44	0.29	0.2	-0.03	-
Shareholders' Equity	-3.65	-4.01	-2.83	-1.72	0.2	2.36
Total Liabilities & Equity	0.68	0.33	0.49	0.67	0.91	2.47
Total Debt	2.31	2.31	1.71	1	-	-
Net Cash (Debt)	-1.68	-2.18	-1.36	-0.44	0.59	2.39
Net Cash Growth	-	-	-	-	-75.21%	1087.94%
Net Cash Per Share	-0.03	-0.05	-0.03	-0.01	0.02	0.14
Filing Date Shares Outstanding	58	58	44.79	39.79	39.79	32.59
Total Common Shares Outstanding	57.5	52.95	44.79	39.79	37.09	32.59
Working Capital	-3.65	-4.01	-2.83	-0.72	0.2	2.36
Book Value Per Share	-0.06	-0.08	-0.06	-0.04	0.01	0.07
Tangible Book Value	-3.65	-4.01	-2.83	-1.72	0.2	2.36
Tangible Book Value Per Share	-0.06	-0.08	-0.06	-0.04	0.01	0.07
Machinery	-	-	-	-	-	0

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.